Literature DB >> 25579166

Peroxiredoxin 1 promotes tumorigenesis through regulating the activity of mTOR/p70S6K pathway in esophageal squamous cell carcinoma.

Fanghua Gong1, Guiqin Hou, Hongtao Liu, Mingzhi Zhang.   

Abstract

The biological function of Peroxiredoxin 1 (Prdx1) in cancer is still ambiguous, and its mechanism has not been elucidated so far. Previous studies have shown that Prdx1 functions as tumor suppressor in several types of cancers, but other studies have indicated that it is overexpressed in some types of human cancers, and inhibition of Prdx1 by shRNA contributes to radiosensitivity and chemosensitivity. In this study, a suppression subtractive hybridization cDNA library between esophageal squamous cell carcinoma (ESCC) cell line EC9706 and noncancerous esophageal epithelial cell line Het-1A was constructed, and 11 tumorigenesis-associated genes including Prdx1 were isolated. In addition, we further confirmed that Prdx1 was overexpressed in ESCC cells at the level of protein compared with Het-1A (P < 0.05). Inhibition of Prdx1 by shRNA lentivirus decreased cell proliferation and invasion, and induced cell apoptosis, but did not affect cell cycle distribution of EC9706 cells (P > 0.05). Importantly, the total proteins of mTOR and p70S6K, as well as the activity of mTOR/p70S6K signaling pathway, were decreased in Prdx1-depletion EC9706 cells. Furthermore, the activity of mTOR/p70S6K signaling pathway was increased in Prdx1-overexpressing Het-1A cells. These findings mentioned above demonstrate that Prdx1 may be involved in tumorigenesis through regulation of mTOR/p70S6K pathway in ESCC.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25579166     DOI: 10.1007/s12032-014-0455-0

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  22 in total

1.  Nuclear factor-kB signaling pathway constitutively activated in esophageal squamous cell carcinoma cell lines and inhibition of growth of cells by small interfering RNA.

Authors:  Fang Tian; Wei-Dong Zang; Wei-Hong Hou; Hong-Tao Liu; Le-Xun Xue
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2006-05       Impact factor: 3.848

2.  Regulation of reactive oxygen species, DNA damage, and c-Myc function by peroxiredoxin 1.

Authors:  Rachel A Egler; Elaine Fernandes; Kristi Rothermund; Susan Sereika; Nadja de Souza-Pinto; Pawel Jaruga; Miral Dizdaroglu; Edward V Prochownik
Journal:  Oncogene       Date:  2005-12-01       Impact factor: 9.867

3.  Proteomics in HepG2 hepatocarcinoma cells with stably silenced expression of PRDX1.

Authors:  Patricia Aguilar-Melero; María-José Prieto-Álamo; Juan Jurado; Arne Holmgren; Carmen Pueyo
Journal:  J Proteomics       Date:  2012-12-28       Impact factor: 4.044

Review 4.  Modulation of neuronal stem cell differentiation by hypoxia and reactive oxygen species.

Authors:  Helena L A Vieira; Paula M Alves; Alessandro Vercelli
Journal:  Prog Neurobiol       Date:  2011-01-18       Impact factor: 11.685

5.  Essential role for the peroxiredoxin Prdx1 in erythrocyte antioxidant defence and tumour suppression.

Authors:  Carola A Neumann; Daniela S Krause; Christopher V Carman; Shampa Das; Devendra P Dubey; Jennifer L Abraham; Roderick T Bronson; Yuko Fujiwara; Stuart H Orkin; Richard A Van Etten
Journal:  Nature       Date:  2003-07-31       Impact factor: 49.962

6.  Up-regulation of peroxiredoxin 1 in lung cancer and its implication as a prognostic and therapeutic target.

Authors:  Joo-Heon Kim; Paul N Bogner; Sun-Hee Baek; Nithya Ramnath; Ping Liang; Hak-Ryul Kim; Chris Andrews; Young-Mee Park
Journal:  Clin Cancer Res       Date:  2008-04-15       Impact factor: 12.531

7.  Tumor suppressor Prdx1 is a prognostic factor in esophageal squamous cell carcinoma patients.

Authors:  Isamu Hoshino; Hisahiro Matsubara; Yasunori Akutsu; Takanori Nishimori; Yasuo Yoneyama; Kentaro Murakami; Haruhito Sakata; Kazuyuki Matsushita; Takenori Ochiai
Journal:  Oncol Rep       Date:  2007-10       Impact factor: 3.906

8.  Proteomic expression analysis of surgical human colorectal cancer tissues: up-regulation of PSB7, PRDX1, and SRP9 and hypoxic adaptation in cancer.

Authors:  Jung-hyun Rho; Shuzhen Qin; Julia Y Wang; Michael H A Roehrl
Journal:  J Proteome Res       Date:  2008-06-13       Impact factor: 4.466

9.  Proteomic analysis of ovarian cancer proximal fluids: validation of elevated peroxiredoxin 1 in patient peripheral circulation.

Authors:  Ebony R Hoskins; Brian L Hood; Mai Sun; Thomas C Krivak; Robert P Edwards; Thomas P Conrads
Journal:  PLoS One       Date:  2011-09-30       Impact factor: 3.240

10.  Prdx1 inhibits tumorigenesis via regulating PTEN/AKT activity.

Authors:  Juxiang Cao; Jennifer Schulte; Alexander Knight; Nicholas R Leslie; Agnieszka Zagozdzon; Roderick Bronson; Yefim Manevich; Craig Beeson; Carola A Neumann
Journal:  EMBO J       Date:  2009-04-16       Impact factor: 11.598

View more
  21 in total

1.  Downregulation of peroxiredoxin II suppresses the proliferation and metastasis of gastric cancer cells.

Authors:  Linjun Niu; Ang Liu; Wei Xu; Liang Yang; Wugang Zhu; Yuming Gu
Journal:  Oncol Lett       Date:  2018-07-25       Impact factor: 2.967

2.  Identification of RAB2A and PRDX1 as the potential biomarkers for oral squamous cell carcinoma using mass spectrometry-based comparative proteomic approach.

Authors:  Kaushik Kumar Dey; Ipsita Pal; Rashmi Bharti; Goutam Dey; B N Prashanth Kumar; Shashi Rajput; Aditya Parekh; Sheetal Parida; Priyanka Halder; Indranil Kulavi; Mahitosh Mandal
Journal:  Tumour Biol       Date:  2015-07-11

3.  Peroxiredoxin 1, a Novel HBx-Interacting Protein, Interacts with Exosome Component 5 and Negatively Regulates Hepatitis B Virus (HBV) Propagation through Degradation of HBV RNA.

Authors:  Lin Deng; Xiang Gan; Masahiko Ito; Ming Chen; Hussein H Aly; Chieko Matsui; Takayuki Abe; Koichi Watashi; Takaji Wakita; Tetsuro Suzuki; Toru Okamoto; Yoshiharu Matsuura; Masashi Mizokami; Ikuo Shoji; Hak Hotta
Journal:  J Virol       Date:  2019-03-05       Impact factor: 5.103

4.  Aberrant expression of peroxiredoxin 1 and its clinical implications in liver cancer.

Authors:  Yu-Lin Sun; Jian-Qiang Cai; Fang Liu; Xin-Yu Bi; Lan-Ping Zhou; Xiao-Hang Zhao
Journal:  World J Gastroenterol       Date:  2015-10-14       Impact factor: 5.742

Review 5.  Peroxiredoxins: guardians against oxidative stress and modulators of peroxide signaling.

Authors:  Arden Perkins; Kimberly J Nelson; Derek Parsonage; Leslie B Poole; P Andrew Karplus
Journal:  Trends Biochem Sci       Date:  2015-06-09       Impact factor: 13.807

6.  Membrane Bound Peroxiredoxin-1 Serves as a Biomarker for In Vivo Detection of Sessile Serrated Adenomas.

Authors:  Sangeeta Jaiswal; Bishnu Joshi; Jing Chen; Fa Wang; Michael K Dame; Jason R Spence; Gina M Newsome; Erica L Katz; Yatrik M Shah; Sadeesh K Ramakrishnan; Gaoming Li; Miki Lee; Henry D Appelman; Rork Kuick; Thomas D Wang
Journal:  Antioxid Redox Signal       Date:  2021-12-21       Impact factor: 8.401

7.  Pro-Apoptotic Effects of JDA-202, a Novel Natural Diterpenoid, on Esophageal Cancer Through Targeting Peroxiredoxin I.

Authors:  Xiao-Jing Shi; Lina Ding; Wenjuan Zhou; Yage Ji; Junwei Wang; Huimin Wang; Yongcheng Ma; Guozhong Jiang; Kai Tang; Yu Ke; Wen Zhao; Hong-Min Liu
Journal:  Antioxid Redox Signal       Date:  2016-11-01       Impact factor: 8.401

8.  Why high cholesterol levels help hematological malignancies: role of nuclear lipid microdomains.

Authors:  Michela Codini; Samuela Cataldi; Andrea Lazzarini; Anna Tasegian; Maria Rachele Ceccarini; Alessandro Floridi; Remo Lazzarini; Francesco Saverio Ambesi-Impiombato; Francesco Curcio; Tommaso Beccari; Elisabetta Albi
Journal:  Lipids Health Dis       Date:  2016-01-12       Impact factor: 3.876

9.  Ets2 knockdown inhibits tumorigenesis in esophageal squamous cell carcinoma in vivo and in vitro.

Authors:  Qinghua Li; Lu Yang; Kang Han; Liqiang Zhu; Yanting Zhang; Shanshan Ma; Kun Zhang; Bo Yang; Fangxia Guan
Journal:  Oncotarget       Date:  2016-09-20

Review 10.  Peroxiredoxin 1 - an antioxidant enzyme in cancer.

Authors:  Chenbo Ding; Xiaobo Fan; Guoqiu Wu
Journal:  J Cell Mol Med       Date:  2016-09-21       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.